Company Insights

ONMD supplier relationships

Explore interactive graphBrowse insights index
ONMD supplier relationship map

OneMedNet (ONMD) — supplier relationships that underwrite its RWD commercialization

OneMedNet operates a regulatory-grade, AI-ready real-world data (RWD) platform branded iRWD™ that aggregates clinical and imaging sources, packages longitudinal specialty datasets, and sells recurring products — principally subscription search and subscription data licenses to life sciences and AI customers. The company monetizes through recurring licensing and dataset commercialization, while outsourcing core platform infrastructure to Palantir and sourcing specialty clinical feeds from third-party data providers. For investors, value will be driven by the pace at which those supplier relationships scale recurring bookings and convert one-off licensing into durable ARR. Visit https://nullexposure.com/ for structured supplier due diligence and monitoring resources.

Supplier posture: what the relationships reveal about how ONMD operates

OneMedNet’s commercial model is a classic aggregator + platform approach: collect clinical signals from a broad set of sites, standardize and curate them on an enterprise analytics backbone, and sell high-margin recurring access to life-science buyers. The supplier roster in public releases highlights three operational realities that investors should mark on their scorecards:

  • Platform dependency and speed-to-market. OneMedNet has publicly tied iRWD™ to Palantir’s technologies (Foundry / AIP), which accelerates product development and commercialization while creating a dependency on a third-party enterprise platform for core data processing and delivery.
  • Supply-side breadth and specialty enrichment. Announced partnerships with niche clinical data providers extend scope into autoimmune and sleep/EEG specialties, enabling premium pricing for hard-to-replicate datasets.
  • Light physical footprint, concentrated professional spend. Company disclosures show a month-to-month office lease and modest rent expense, but audit fees in the high six-figures, reflecting heavier spend on professional services and governance rather than fixed infrastructure.

These signals indicate a contracting posture oriented to scalable, service-provider relationships over capital-intensive build, with supplier concentration on a few strategic technology and data partners rather than a large roster of equal contributors.

Relationship roster — who ONMD is working with and what each brings

ViuHealth

ViuHealth will supply ongoing, longitudinal autoimmune disease data to OneMedNet, expanding the company’s specialty dataset catalog and supporting life-science research and AI model development; the announcement positions this feed as a revenue-accretive input to recurring dataset licenses (Sahm Capital press release, Feb 26, 2026; Yahoo Finance coverage, Mar 10, 2026).
Source: Sahm Capital (Feb 26, 2026) and Yahoo Finance (Mar 10, 2026).

Palantir Technologies Inc. (PLTR)

Palantir Technologies is cited as the enterprise partner powering OneMedNet’s commercial launch of the iRWD platform, which the company uses to accelerate product delivery and scale subscription offerings (Benzinga coverage of the Palantir-powered launch, Feb 27, 2026).
Source: Benzinga (Feb 27, 2026).

Palantir Technologies (alternate mentions)

Company communications and shareholder letters reiterate selection of Palantir’s AI and Foundry stack as a strategic accelerant for OneMedNet’s AI-driven multimodal subscription search product, framing Palantir as a strategic technology backbone for platform features (Shareholder letter and company releases, Dec 2025).
Source: OneMedNet shareholder letter and related company releases (Dec 2025).

Palantir Foundry

OneMedNet’s iRWD™ platform is explicitly described as “powered by Palantir Foundry,” which the company uses to enable rapid cohort identification, multimodal data curation, and secure delivery of de-identified, regulatory-grade outputs — language used across press releases announcing the commercial launch (Sahm Capital / GlobeNewswire, Feb 2026 and Aug 2025).
Source: Sahm Capital press release (Feb 27, 2026) and GlobeNewswire (Aug 14, 2025).

Palantir AIP Foundry

Public statements highlight Palantir’s AIP Foundry as the execution environment enabling OneMedNet to deliver scaled feeds (e.g., a reported 1.5M patient feed) and reduce integration risk for customers — the messaging signals production-level deployment of Palantir capabilities to support data licensing (QuiverQuant / company releases, Jan 2026).
Source: QuiverQuant report (Jan 16, 2026).

Palantir (general references)

Multiple press items and booking commentary tie OneMedNet’s acceleration of bookings and a growing premium recurring revenue funnel directly to solutions “powered by Palantir Foundry,” underlining the commercial as well as technical role Palantir plays in the company’s go-to-market narrative (GlobeNewswire and company booking announcements, Feb 2026).
Source: GlobeNewswire / OneMedNet press releases (Feb 12, 2026).

Risorius

OneMedNet announced a multi-year data licensing deal with Risorius that is positioned to deliver high-value EEG and polysomnography datasets, aimed at supporting R&D and AI model development for sleep and neurology use cases and adding specialty recurring-license revenue (StocksToTrade coverage, Feb 27, 2026).
Source: StocksToTrade (Feb 27, 2026).

What the supplier mix implies for risk, scalability, and valuation

  • Dependency risk is material but compensated by capability. The Palantir relationship is central: it shortens ONMD’s time-to-market and enables enterprise-grade delivery, but it increases vendor dependency and potential switching costs. Investors should value the trade-off between accelerated commercialization and single-vendor concentration.
  • Commercialization runway looks credible if specialty feeds scale. Partnerships with ViuHealth and Risorius expand differentiated content that commands premium pricing; converting those content types into stable subscription ARR is the explicit path to justify current market perceptions of future revenue. The core investment question is conversion velocity from bookings into contracted recurring revenue.
  • Cost structure favors variable supplier and professional spend. Disclosures show a month-to-month lease and modest rent but material audit fees (~$790k in 2024), signaling that operating leverage will come from scaling data licenses rather than reducing fixed costs. Professional services and platform fees are the primary near-term burn drivers.

Constraints and company-level signals investors should track

Company excerpts show a month-to-month office lease, which indicates a lean physical footprint and operational flexibility. OneMedNet classifies its data sources as service-provider relationships with access to over 1,400 healthcare sites, a signal of breadth rather than single-source concentration on the supply side. Reported audit fees (~$790k) place professional services in the mid-six-figure band, while rent expense is immaterial by comparison. These are company-level signals of a software-lite, networked supply model that relies on third-party platform and data suppliers for scale.

If you are modeling ONMD, stress-test scenarios where platform costs (Palantir) scale with revenue and where conversion of specialty feeds to multi-year subscriptions lags expectations.

For a deeper supplier-risk and opportunity assessment, visit https://nullexposure.com/ to request structured due diligence and ongoing supplier monitoring.

Bottom line and investor action points

  • Palantir is both a growth enabler and a concentration risk; assess the terms and longevity of that integration in diligence.
  • Specialty data partnerships (ViuHealth, Risorius) create pricing leverage if OneMedNet can lock multi-year licensing deals and migrate clients to subscription models.
  • Operational spend is skewed toward governance and platform fees, not real estate, which helps scalable margin expansion once ARR ramps.

If your investment thesis depends on accelerating recurring revenue from premium clinical feeds, prioritize supplier contract review (term lengths, exclusivity, data refresh cadence) and monitor bookings-to-ARR conversion. For tailored supplier intelligence and live tracking of these relationships, explore services at https://nullexposure.com/.

Conclude diligence by focusing on contract terms with Palantir and the pipeline of conversions from announced specialty feeds into repeatable subscription revenue — those two levers will determine whether OneMedNet’s public narrative translates into sustainable cash flows.